A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors.

Trial Profile

A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Breast cancer; Carcinoma; Fallopian tube cancer; Gastric cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Uveal melanoma
  • Focus Therapeutic Use
  • Sponsors Exelixis
  • Most Recent Events

    • 26 Jul 2017 Results (N=70) of ovarian carcinoma cohort published in the European Journal of Cancer
    • 10 Jun 2017 Biomarkers information updated
    • 01 Mar 2017 Results from the hepatocellular carcinoma (n=41) cohort published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top